Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

5 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

6(66.7%)

Phase 2

3(33.3%)

9Total

Phase 1(6)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07265570Phase 2Recruiting

Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)

Role: lead

NCT06566079Phase 1Recruiting

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

Role: lead

NCT05938920Phase 2Completed

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Role: lead

NCT06414460Phase 1Recruiting

Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors

Role: lead

NCT06724042Phase 1Not Yet Recruiting

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

Role: lead

NCT05975983Phase 2Recruiting

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

Role: lead

NCT06012578Phase 1Completed

Study Evaluating ISM5411 Administered Orally to Healthy Volunteers

Role: lead

NCT06445517Phase 1Recruiting

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Role: lead

NCT05154240Phase 1Completed

A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects

Role: lead

All 9 trials loaded